Skip to main content

IBM, Cellomics Partner on HCS IT Infrastructure; Sell First System to EPOPlus

NEW YORK, Aug. 11 (GenomeWeb News) - IBM and Cellomics said yesterday that they have jointly developed a customized information technology solution for Cellomics' high-content screening platform.


The companies said that the first of these "turnkey" IT infrastructures has already been installed at EPOPlus, a biotech firm developing erythropoietin therapies.


The infrastructure, called the HCi Appliancel, includes Cellomics' High Content Informatics software with servers, storage and management software from IBM.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.